| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888364 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Nov, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9790183 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Sep, 2025
(1 year, 4 months from now) | |
| US9278961 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Dec, 2028
(4 years from now) | |
Erivedge is owned by Genentech.
Erivedge contains Vismodegib.
Erivedge has a total of 3 drug patents out of which 0 drug patents have expired.
Erivedge was authorised for market use on 30 January, 2012.
Erivedge is available in capsule;oral dosage forms.
Erivedge can be used as method of using vismodegib to treat cancer in a mammal, method of using vismodegib to treat basal cell carcinoma.
Drug patent challenges can be filed against Erivedge from 31 January, 2016.
The generics of Erivedge are possible to be released after 15 December, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2017 |
Drugs and Companies using VISMODEGIB ingredient
NCE-1 date: 31 January, 2016
Market Authorisation Date: 30 January, 2012
Treatment: Method of using vismodegib to treat basal cell carcinoma; Method of using vismodegib to treat cancer in a mammal
Dosage: CAPSULE;ORAL
ERIVEDGE family patents
